Regulus Acquires miRNA IP from NYU

The intellectual property relates to two miRNAs, miR-33a and miR-33b, as drug targets for metabolic diseases.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.